Heptares raises $21m in tie-up with Stanley foundation
This article was originally published in Scrip
Executive Summary
Heptares Therapeutics, a GPCR-focused drug discovery and development company, has raised $21m in a series B financing to advance a pipeline of novel drugs directed towards clinically validated targets for the treatment of neurological and psychiatric diseases. The financing round was co-led by the Stanley Family Foundation (SFF), a leading neuroscience disease foundation, and current investor Clarus Ventures with Takeda Ventures also participating.